studing the therapeutic effect of baricitinib and its side effects in LPP (Lichen Plano Pilaris)
- Conditions
- lichen planopilaris.Chapter XII Diseases of the skin and subcutaneous tissue(L00-L99)
- Registration Number
- IRCT20221101056374N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 22
Age between 15 and 70 years
Acceptance of all provisions of informed consent regarding the plan
Absence of contraindications for baricitinib use, including chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding
Not being pregnant and not taking OCP
Severe and expanding multifocal disease that is a candidate for receiving systemic medication according to the opinion of the main executive of the plan.
Not taking drugs that interact with baricitinib
The patient's consent to enter the plan
For any reason, the patient does not agree to enter the plan
For any reason, the patient does not agree with the provisions of informed consent in the plan
Contraindications to baricitinib use include chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding
Pregnancy or OCP consumption
Local and limited disease that is not a candidate for receiving systemic and immunosuppressive drugs according to the opinion of the main executive of the plan.
Taking drugs that interfere with baricitinib
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method